Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News Briefs: Invacare Update; Patent Trolls; VC Trends

This article was originally published in The Gray Sheet

Executive Summary

Invacare reports its earnings are hindered by an FDA consent decree, but management hopes to be released from the agreement soon. The American Hospital Association signs onto a letter to Congress calling for a crackdown on so-called “patent trolls.” More news in brief

You may also be interested in...



Patent Troll Lawsuits Rare In Device Industry, But May Increase, Attorneys Say

Patent attorneys suggest lawsuits from firms that buy up device patents purely to pursue litigation, which appears to have occurred recently with Medtronic’s kyphoplasty patents, may become a more common occurrence.

News In Brief

Obama signs appropriations bill giving FDA expanded user fee access. Bausch & Lomb IPO. More news.

Physician-Initiated Alert Sparks Zimmer Investigation Of Durom Hip Failures

Zimmer is investigating failures of its Durom hip implants after a prominent joint reconstruction surgeon sent a letter reporting a series of problems with the device to the American Association of Hip and Knee Surgeons

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT032271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel